Last reviewed · How we verify
Nuvaxovid
Nuvaxovid is a Biologic drug developed by Tan Tock Seng Hospital. It is currently FDA-approved.
Nuvaxovid, marketed by Tan Tock Seng Hospital, is a vaccine with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the hospital's established healthcare network. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Nuvaxovid |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Reactogenicity (PHASE4)
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PHASE4)
- COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nuvaxovid CI brief — competitive landscape report
- Nuvaxovid updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI
Frequently asked questions about Nuvaxovid
What is Nuvaxovid?
Who makes Nuvaxovid?
What development phase is Nuvaxovid in?
Related
- Manufacturer: Tan Tock Seng Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing